Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-08-13 Major Shareholding Noti…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2024-08-13 English
3
Director's Dealing
2024-08-13 English
6-K
Regulatory Filings
2024-08-13 English
Sanofi: Information concerning the total number of voting rights and shares - July 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns the 'total number of voting rights and shares' pursuant to French commercial code and AMF regulations. It provides a table detailing the total number of issued shares and the corresponding number of voting rights as of a specific date (July 31, 2024). This type of mandatory disclosure regarding the capital structure and voting power is a specific regulatory filing. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS), but rather a periodic disclosure of the total voting rights base. This fits best under the general 'Regulatory Filings' (RNS) category as it is a specific, recurring regulatory disclosure required by the French market authority (AMF) that doesn't align perfectly with the other specialized codes like DIV, CAP, or DVA (which is for voting *results*). Given the specific nature of the disclosure (voting rights count), RNS is the most appropriate fallback for mandatory regulatory updates not covered elsewhere.
2024-08-09 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers". It provides a table detailing the total number of shares and voting rights as of a specific date (July 31, 2024), referencing French commercial code and AMF regulations. This type of mandatory disclosure regarding the total voting power and share capital structure is a specific regulatory filing requirement, often related to shareholder structure or capital changes, but it is not a full report (10-K, IR) nor a general announcement (RNS). It most closely aligns with a specific regulatory disclosure concerning capital structure or voting rights. Given the options, while it relates to voting rights, it is a mandatory disclosure of the total count, not the results of a vote (DVA) or a general proxy solicitation (PSI). Since it is a specific, periodic regulatory disclosure about the capital structure and voting rights count, and not a general announcement about a report, it fits best under the general 'Regulatory Filings' (RNS) as a specific, non-standard category, or potentially related to capital structure changes (SHA). However, since it is a mandatory disclosure of the total voting rights count, which is a specific regulatory requirement often published outside of the main annual/interim reports, RNS is the most appropriate fallback for specific regulatory data disclosures not covered elsewhere. Upon re-evaluation, the content is purely about the total number of shares and voting rights, which is a specific regulatory disclosure. It is not a DVA (Declaration of Voting Results), but a statement of the current capital structure for voting purposes. Given the highly specific nature of the French regulatory reference (L. 233-8 II), and the lack of a perfect fit, RNS (Regulatory Filings) serves as the best general category for mandatory, specific regulatory updates that aren't earnings, management changes, or dividend notices. The document length is short, but it is the report itself, not an announcement of a report.
2024-08-09 French
Communiqué : Le traitement d’induction par Sarclisa a démontré une amélioration significative de la survie sans progression chez les patients atteints d’un myélome multiple nouvellement diagnostiqué e
Earnings Release Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and is dated August 8, 2024. It details positive clinical trial results (GMMG-HD7 study) for a drug (Sarclisa) in treating multiple myeloma. This format—a formal announcement of significant business/clinical news, often including quotes from management and study investigators, and concluding with boilerplate information about the company and contacts—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is announcing clinical trial results rather than periodic financial performance (like revenue/net income), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, it best fits the 'Earnings Release' category (ER) as the primary vehicle for disseminating major, time-sensitive corporate news, even if the content is scientific rather than purely financial. It is not a Report Publication Announcement (RPA) because it contains the substantive information itself, not just a notice that a report is available. FY 2024
2024-08-08 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.